We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q4
Read MoreHide Full Article
Immune Design Corp. reported loss of 29 cents per share in fourth-quarter 2017 results, narrower than the Zacks Consensus Estimate of a loss of 39 cents and the year-ago quarter’s loss of 57 cents.
Immune Design’s shares have lost 37.5% year to date compared with the industry’s rally of 4.3%.
Quarter in Detail
Total revenues were $0.5 million, down from $2.1 million in the year-ago quarter. Revenues received from the collaboration with Sanofi (SNY - Free Report) for G103 (HSV2 therapeutic cancer) contributed majorly. Quarterly revenues missed the Zacks Consensus Estimate of $1 million.
Research and development (R&D) expenses declined 29% to $8.5 million in the quarter. The downturn was due to the decrease in clinical trial costs as a result of the timing of when the related costs associated with Immune Design’s current clinical trials were incurred. A decrease in in-licensing royalties and fees attributable to the settlement and license agreements with Theravectys in October 2016 and a decline in contract manufacturing costs activities primarily owing to the timing of when services are performed also led to the decline.
General and administrative expenses fell 2.7% to $4.3 million.
Pipeline Update
Immune Design is developing multiple candidates using its discovery platforms — ZVex and GLAAS — in the field of immuno-oncology. Notably, its key pipeline candidates include CMB305 and G100.
Following discussions with the FDA, the company announced plans to initiate a pivotal phase III study to support a Biologics License Application for CMB305 on patients with synovial sarcoma. Progression free survival (PFS) and overall survival (OS) will become independent primary endpoints. Post the success of PFS, the FDA may forward approval. The company plans to initiate the study in mid-2018.
Additionally, the company presented interim analysis of CMB305 Combination Therapy at ASCO in June 2017. Per the analysis, NY-ESO-1+ synovial sarcoma or mixoid round cell liposarcoma patients, receiving the combination of CMB305 and Roche Holding AG’s (RHHBY - Free Report) Tecentriq, experienced greater clinical benefit in the form of Disease Control Rate (including partial responses), median Progression Free Survival, Time to Next Treatment and immune response compared with those receiving Tecentriq alone.
Meanwhile, CMB305 is being evaluated for soft tissue sarcoma (STS) patients as monotherapy and in combination with an anti-PD-L1 antibody. In fact, the company presented CMB305 monotherapy data at ASCO from 25 STS patients with recurrent disease. Per the data, median overall survival (mOS) has not yet been reached in these patients, with an overall survival rate at 12 and 18 months of 83% and 76%, respectively. The company also presented updated data from this study in March 2018. The data showed that with a median follow-up of 17.7 months, a median overall survival (mOS) of 23.7 months has been reached for the whole population but not yet for the synovial sarcoma patient subset.
The company also provided updated data for G100 later in the month. The data showed that with a median follow-up of approximately 12 months, the objective response rate (ORR) in the combination arm (G100+XRT in combination with pembrolizumab) increased from 39-54%, while the ORR of G100+XRT is constant at 15%.
2017 Results
Immune Design reported a loss of $1.75 per share in 2017, narrower than the Zacks Consensus Estimate of a loss of $1.89 and also the year-ago loss of $2.47.
Total revenues for 2017 were $7.2 million, down from $13.3 million in the year-ago quarter.
2018 Outlook
Immune Design expects cash to fund operations into the second half of 2020.
Immune Design Corp. Price, Consensus and EPS Surprise
Regeneron’s earnings estimates have inched up from $18.65 to $18.67 and from $21.56 to $21.58 for 2018 and 2019, respectively, in the last 30 days. The company pulled off a positive earnings surprise in three of the last four quarters, with an average beat of 9.15%.
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others. Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Image: Bigstock
Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q4
Immune Design Corp. reported loss of 29 cents per share in fourth-quarter 2017 results, narrower than the Zacks Consensus Estimate of a loss of 39 cents and the year-ago quarter’s loss of 57 cents.
Immune Design’s shares have lost 37.5% year to date compared with the industry’s rally of 4.3%.
Quarter in Detail
Total revenues were $0.5 million, down from $2.1 million in the year-ago quarter. Revenues received from the collaboration with Sanofi (SNY - Free Report) for G103 (HSV2 therapeutic cancer) contributed majorly. Quarterly revenues missed the Zacks Consensus Estimate of $1 million.
Research and development (R&D) expenses declined 29% to $8.5 million in the quarter. The downturn was due to the decrease in clinical trial costs as a result of the timing of when the related costs associated with Immune Design’s current clinical trials were incurred. A decrease in in-licensing royalties and fees attributable to the settlement and license agreements with Theravectys in October 2016 and a decline in contract manufacturing costs activities primarily owing to the timing of when services are performed also led to the decline.
General and administrative expenses fell 2.7% to $4.3 million.
Pipeline Update
Immune Design is developing multiple candidates using its discovery platforms — ZVex and GLAAS — in the field of immuno-oncology. Notably, its key pipeline candidates include CMB305 and G100.
Following discussions with the FDA, the company announced plans to initiate a pivotal phase III study to support a Biologics License Application for CMB305 on patients with synovial sarcoma. Progression free survival (PFS) and overall survival (OS) will become independent primary endpoints. Post the success of PFS, the FDA may forward approval. The company plans to initiate the study in mid-2018.
Additionally, the company presented interim analysis of CMB305 Combination Therapy at ASCO in June 2017. Per the analysis, NY-ESO-1+ synovial sarcoma or mixoid round cell liposarcoma patients, receiving the combination of CMB305 and Roche Holding AG’s (RHHBY - Free Report) Tecentriq, experienced greater clinical benefit in the form of Disease Control Rate (including partial responses), median Progression Free Survival, Time to Next Treatment and immune response compared with those receiving Tecentriq alone.
Meanwhile, CMB305 is being evaluated for soft tissue sarcoma (STS) patients as monotherapy and in combination with an anti-PD-L1 antibody. In fact, the company presented CMB305 monotherapy data at ASCO from 25 STS patients with recurrent disease. Per the data, median overall survival (mOS) has not yet been reached in these patients, with an overall survival rate at 12 and 18 months of 83% and 76%, respectively. The company also presented updated data from this study in March 2018. The data showed that with a median follow-up of 17.7 months, a median overall survival (mOS) of 23.7 months has been reached for the whole population but not yet for the synovial sarcoma patient subset.
The company also provided updated data for G100 later in the month. The data showed that with a median follow-up of approximately 12 months, the objective response rate (ORR) in the combination arm (G100+XRT in combination with pembrolizumab) increased from 39-54%, while the ORR of G100+XRT is constant at 15%.
2017 Results
Immune Design reported a loss of $1.75 per share in 2017, narrower than the Zacks Consensus Estimate of a loss of $1.89 and also the year-ago loss of $2.47.
Total revenues for 2017 were $7.2 million, down from $13.3 million in the year-ago quarter.
2018 Outlook
Immune Design expects cash to fund operations into the second half of 2020.
Immune Design Corp. Price, Consensus and EPS Surprise
Immune Design Corp. Price, Consensus and EPS Surprise | Immune Design Corp. Quote
Zacks Rank & Key Pick
Immune Design carries a Zacks Rank #3 (Hold).
A better-ranked stock from the same space is Regeneron (REGN - Free Report) sporting a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Regeneron’s earnings estimates have inched up from $18.65 to $18.67 and from $21.56 to $21.58 for 2018 and 2019, respectively, in the last 30 days. The company pulled off a positive earnings surprise in three of the last four quarters, with an average beat of 9.15%.
Can Hackers Put Money INTO Your Portfolio?
Earlier this month, credit bureau Equifax announced a massive data breach affecting 2 out of every 3 Americans. The cybersecurity industry is expanding quickly in response to this and similar events. But some stocks are better investments than others. Zacks has just released Cybersecurity! An Investor’s Guide to help Zacks.com readers make the most of the $170 billion per year investment opportunity created by hackers and other threats. It reveals 4 stocks worth looking into right away.
Download the new report now>>